HISTORY
The start 2006
CarpoNovum is founded by
two colorectal surgeons
Prof. Henrik Thorlacius, MD, PhD and
Anders Grönberg, MD, PhD, engineer
Award 2006
CarpoNovum received
Öhrlings Price Water House Coopers and LUIS Innovation awards
Award 2007
CarpoNovum received the
national Skapa
Development Award
Award 2007
CarpoNovum received the
award for the most successful company in the Connect
Sweden network
CE 2011
CARP®, predecessor
of C-REX®, received
CE marking
Developing 2011-2018
C-REX® device family was developed, clinical studies were conducted in Sweden, Denmark and China.
CE 2018
CE marking of the
C-REX® family
Scandinavian CCS 2020
A subsidiary of CarpoNovum AB,
is formed for surgical
education and
clinical practice.
Clinical trial in Malmö,
Sweden 2023
Investigator initiated study successfully finalized, see article.
Anders Grönberg
Henrik Thorlacius
Otto Drakenberg
Chairman of the Board
​
Otto Drakenberg is the chairman of the board of Spendrups Brewery, Svegro and Sisjö Intressenter and CEO of SMD Logistics. His former operational experience include CEO roles in listed and privately held companies such as Scandi Standard, Moment Group, and Nordic beverage group Arcus.
Lars Johansson
Member of the Board
​
Lars Johansson Brings 30 years of experience from the medtech and pharmaceutical industry, including 13 years as General Manager for Johnson & Johnson in the Nordics. Lars has a track record of being an extraordinary leader and his experience covers all strategic and operational aspects of bringing innovative treatments to patients.
Tom Øresland
Member of the Board and Chairman of the Advisory Board
​
Tom Øresland professor emeritus at the University of Oslo has been working as a colorectal surgeon for almost half a decade. Tom has published extensively in the fields of colorectal surgery with special interests in inflammatory bowel disease. He has a broad international network within the European Society of Colorectal surgery and is an elected member of the International Organisation for the study of Inflammatory Bowel Diseases. Tom has also been involved in the development of surgical innovations.
ADVISORY BOARD
Anna Martling, prof.
Clinical advisor
​
Anna Martling is a Professor of Surgery at Karolinska Institutet, Stockholm, Sweden. She defended her thesis on rectal cancer in 2003, became a board certified surgeon in 2004 and an associate professor of surgery in 2009. In 2014 Martling became full professor of surgery. Since 2019 she holds the position as Dean at Karolinska Institutet, Stockholm.
She is considered to be a world leading expert in her field and is a frequent lecturer in Sweden and abroad. Professor Martling is Honorary Fellow of Royal College of Surgeon of England, (FRCS), American Colleges of Surgeons (FACS) and American Society of Colorectal Surgeons (FASCRS). Professor Martling is chairman of the Swedish Colorectal Cancer Study Group, which is a national research network for colorectal cancer in Sweden. Professor Martling has received numerous awards for her research within the colorectal field and in 2023 she was appointed honorary member of the European Society of Coloproctology (ESCP) which is awarded to individuals who have made an outstanding contribution to the field of coloproctology.
​
Photo from Karolinska Institutet.
Janindra Warusavitarne
Clinical advisor
​
Janindra Warusavitarne is a consultant colorectal surgeon at St Mark's Hospital in London. He obtained his medical education and training in Australia and was invited to join the staff at St Mark's Hospital in 2023. His area of expertise is Inflammatory bowel diseases, proctology, pelvic floor issues and Intestinal rehabilitation. He is an internationally recognised surgeon with over 220 peer reviewed publications and 15 book chapters. His h index of 53. He is a member of the executive committee of the European Society of coloproctology (ESCP)
Dr. Anthony de Buck, MD, MSc.
Clinical Advisor
​​
Dr. Anthony de Buck is a colorectal surgeon and internationally recognized expert in inflammatory bowel disease (IBD). He currently practices at the Cleveland Clinic in Ohio, where he serves as colorectal surgeon and Lead of the IBD Section within the Department of Colorectal Surgery. He also holds an academic appointment as Visiting Associate Professor of Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
​
Dr. de Buck recently transitioned from Mount Sinai Hospital in Toronto, where he practiced as a colorectal surgeon and served as Associate Professor of Surgery at the University of Toronto. His move reflects a continued commitment to advancing surgical care and academic leadership in IBD.
​
He earned his medical degree at the University of Leuven, where he also completed comprehensive surgical and colorectal training. In 2013, he completed a colorectal fellowship at the University of Toronto, refining his expertise under the mentorship of leading figures in the field.
​
In addition to his clinical training, Dr. de Buck holds a Master’s Degree in Clinical Epidemiology from the University of Toronto, equipping him with advanced skills to lead rigorous, outcome-driven research.
​
His research focuses on clinical outcomes in IBD, particularly functional results and quality of life. He has led and contributed to numerous multi-institutional studies and randomized controlled trials, supported by peer-reviewed funding. His work continues to influence surgical practice and improve care for patients with IBD.
​
As an engaged educator, Dr. de Buck remains actively involved in the teaching and mentorship of medical students, residents, and fellows. His dedication to academic excellence and patient-centered innovation has earned him widespread recognition as a leader in colorectal surgery.
Per J. Nilsson
Clinical Advisor
​​
Per J. Nilsson holds a position as a senior consultant colorectal surgeon at Karolinska University Hospital and as Associate Professor & Senior Lecturer at Karolinska Institutet, Stockholm, Sweden. He has previously served as President of both the Swedish Society of Colon & Rectal Surgeons and the European Society of Coloproctology (ESCP). Nilsson is a member of the PI group for the international RAPIDO trial and subsequently in the steering board of the Swedish LARCT-US study, both on locally advanced rectal cancer. Nilsson is a renowned expert in his field and has an extensive international network within the colorectal surgery and oncology community.
Will Rutan
Regulatory Advisor
​​
Will Rutan is an accomplished start-up executive in the medical device industry. He has a proven track record in steering regulatory approval processes, and is an expert in strategic positioning, fundraising, marketing and sales strategies, design and development oversight, and market penetration strategies.
FINANCIAL ADVISORY BOARD
Johan Stein
Financial advisor
​​
Lecturer and researcher at Stockholm School of Economics for 10 years. He gained a doctorate degree in 2011, later named docent and professor. Has been Head of research and portfolio manager at a number of hedge funds and with Nordea Investment Management. Also has experience from Alfred Berg and BNP Paribas.
Christophe Genetay
Financial advisor and Head of Investor Relations
​​
M.Sc. Civ Eng. and has 25 years experience in the financial industry, working with listed and non-listed companies. Former head of training at the Swedish Council for small investors. Since 2013 been engaged with Investor Relations across various industries.
Q&R
Quality and Regulatory
C-REX® devices are CE-marked in Europe. Regulatory approval has been achieved by complying with Medical Device Directive 93/42/EC as Class IIa devices and CarpoNovum holds a certificate of current version of EN ISO 13485.
Quality policy
All team members of CarpoNovum are committed to improve lives of people undergoing colorectal surgery, by providing high-quality, safe and effective products and services that meet our customers’ needs, with focus on continual improvement, by:
-
having a close collaboration with leading surgeons and health care professionals
-
complying with all applicable regulatory requirements
-
continually improving the effectiveness of our Quality Management System
-
periodically reviewing the performance of the Quality Management System and our Quality Objectives
-
communicating this Quality Policy to all team members, subcontractors and suppliers to assure that it is understood and implemented
​
​